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T he standard radiation therapy for cervical cancer is a combination of external beam radiotherapy 
(EBRT) and brachytherapy (BT) [1].  BT is an important 
component of the treatment [2],  and three-dimen-
sional image-guided BT (3D-IGBT) using computed 
tomography (CT) or magnetic resonance imaging 
(MRI) is widely employed [3 , 4].  Moreover,  there are 
several reports on treatment outcomes of and risk fac-
tors for local control in IGBT of cervical cancer [5-10].
There are 2 distinct radiotherapy approaches that 
aim to improve outcomes: those that use central shield-
ing (CS) and those that do not.  In comparison to 
American and European nations [7-9 , 11],  in Japan 
treatment schedules using CS are included in the guide-
lines [12].  Outcomes have been reported based on each 
treatment schedule [7-10].  The dose volume parameter,  
an important local control factor in cervical cancer,  
suggests differences in the dose required for local con-
trol depending on whether or not CS is used [7-10],  and 
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The purposes of this retrospective study were to analyze local control of squamous cell carcinoma of the cervix 
treated with computed tomography (CT)-based image-guided brachytherapy (IGBT),  as well as the factors 
affecting local control.  A total of 39 patients were analyzed.  The prescribed dose to the pelvis was 45-50 Gy 
with or without central shielding (CS).  IGBT was delivered in 1-5 fractions.  The total dose for high-risk clinical 
target volume (HR-CTV) was calculated as the biologically equivalent dose in 2-Gy fractions.  The median 
follow-up period was 29.3 months.  The 2-year overall survival and local control rates were 97% and 91%,  
respectively.  In univariate analysis,  the dose covering 90% of the HR-CTV (D90) and tumor size were found to 
be significant factors for local control.  The cutoff values of tumor size and D90 for local control were 4.3 cm 
(area under the curve [AUC] 0.75) and 67.7 Gy (AUC 0.84) in the CS group and 5.3 cm (AUC 0.75) and 73.7 Gy 
(AUC 0.78) in the group without CS,  respectively.  However,  though the local control of CT-based IGBT was 
favorable,  the results suggested that the dose required for tumor control may differ depending on the presence 
of CS.
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these differences raise questions in clinical practice.
At our institution,  we have implemented treatments 
both with and without CS.  However,  to our knowledge 
there have been no reports examining the dose volume 
parameter for local control for each treatment schedule 
at the same facility.  Therefore,  one of the purposes of 
this study was to examine the local control rate for cer-
vical squamous cell carcinoma as well as the factors 
affecting local control,  including CS of CT-based 
3D-IGBT.  Additionally,  we examined the dose volume 
parameters necessary for local control in each treatment 
schedule.
Patients and Methods
Patients. This study was approved by the institu-
tional Ethics Committee (No. 916) of the Kagawa 
Prefectural Central Hospital,  Kagawa.  Informed con-
sent to participate was obtained from all patients.  A 
total of 39 patients with pathologically proven,  previ-
ously untreated squamous cell carcinoma of the cervix 
were treated at our hospital with high-dose-rate (HDR) 
CT-based 3D-IGBT between August 2014 and April 
2019,  and were included in this study.  All radiotherapy 
(RT) and concurrent chemoradiotherapy (CCRT) were 
definitive treatments.  All patients underwent a pelvic 
examination,  CT scan,  MRI,  and blood test.  
Maximum tumor diameters were measured based on 
the axial images of MRI.  Patients with 2008 
International Federation of Gynecology and Obstetrics 
(FIGO) Stage IB1-IVA disease were included.  Patients 
with para-aortic node metastasis were included because 
this study was performed to analyze local control of the 
primary tumor.
Chemotherapy. Concurrent chemotherapy of 
cisplatin (40 mg/m2) and nedaplatin (35 mg/m2) was 
administered weekly to 30 patients (77%).  CCRT was 
not performed in patients with insufficient organ func-
tions or in those aged 80 years or older.  Supportive 
treatments,  such as blood transfusions,  were per-
formed during RT/CCRT.
External beam radiotherapy. EBRT was deliv-
ered by CT-based planning with 4-10 MV X-rays.  The 
clinical target volume (CTV) for EBRT included sites 
such as the primary tumor,  whole uterus,  bilateral 
parametrium,  at least the upper half of the vagina,  and 
pelvic lymph nodes (common,  internal,  external iliac,  
obturator,  and presacral).  If the primary tumor 
involved the lower third of the vagina or if there were 
enlarged inguinal lymph nodes,  the inguinal regions 
were also included in CTV.  The planning target volume 
(PTV) was defined as CTV plus a 1- to 2-cm margin of 
primary tumor and uterus body.  PTV margins for other 
CTV were set to 5 mm to account for daily setup errors.  
Three-dimensional conformal RT (3D-CRT) with an 
anterior－posterior parallel-opposed field or a 4-field 
box was used for whole pelvic (WP) irradiation.  After 
WP irradiation,  the anterior－posterior parallel-op-
posed field with a 4-cm-wide CS was delivered accord-
ing to the Japanese guidelines [12].  The position of CS 
was set to the S2/3 level.  We started volumetric modu-
lated arc therapy (VMAT) for WP irradiation from 
April 2016.  VMAT was performed using 2-4 arcs.  We 
normalized each plan such that 100% of the prescribed 
dose was delivered to 95% of the PTV.  The total pelvic 
dose administered was 45-50 Gy.  For patients with 
lymph node metastases or inadequate tumor regression 
after WP irradiation,  an additional boost was delivered 
to make the dosage 55-61 Gy.
Brachytherapy. BT was initiated after WP-EBRT 
and was performed weekly for a total of 1-5 sessions.  A 
high-dose-rate (HDR) 60Co source was used for the 
treatment.  Intracavitary (IC) BT or the combination of 
IC and interstitial (IS) BT was performed to adapt to the 
tumor volume.  The IS technique was considered for 
large (e.g., ≥ 4 cm) or asymmetric tumors.  CT-based 
3D-IGBT was performed during each BT session.  The 
high-risk CTV (HR-CTV) and organs at risk (OARs),  
including the rectum and bladder,  were contoured on 
planning CT with reference to MRI images acquired at 
diagnosis and just before the first BT session.  The 
HR-CTV included the entire cervix and the residual 
macroscopic tumor at the time of BT [13].  OARs were 
delineated based on pelvic normal tissue contouring 
guidelines [14].  All radiation doses were biologically 
converted to equivalent doses in 2 Gy (EQD2) by a lin-
ear quadratic model using an alpha/beta ratio of 10 Gy 
for HR-CTV and 3 Gy for OARs.  The dwell times and 
dose distributions were modified manually using 
graphical optimization to meet our dose constraints: (i) 
for each BT session,  HR-CTV D90 ≥ 6 Gy,  bladder and 
rectum D2 cc < 7 Gy (where D2 cc means the dose deliv-
ered to 2 cc of OARs); (ii) total HR-CTV D90 ≥ 60 Gy,  
bladder D2 cc < 90 Gy,  rectum D2 cc < 75 Gy.  In the cal-
culation of the total HR-CTV and OAR doses,  all the 
EQD2 values of WP-EBRT (not including CS-EBRT) 
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and HDR-BT were summed because CS-EBRT is con-
sidered not to contribute to the HR-CTV or OARs in 
the Japanese treatment schedule [6 , 10].
Follow-up. Gynecologists and radiation oncolo-
gists followed up each patient every 1-3 months for the 
first 2 years and every 3-6 months from the third year 
after completion of the treatment.  Tumor status and 
adverse events were assessed using patient interviews,  
physical and gynecological examinations,  and blood 
tests.  Patients generally underwent CT and/or MRI at 
1-3 months after treatment to evaluate the therapeutic 
effects and every 6-12 months thereafter.  Recurrent 
disease was confirmed by biopsy,  though the presence 
of recurrence was determined when a lesion was clearly 
seen on imaging (CT or MRI) before the malignancy 
could be confirmed via biopsy.  Local control (LC) dura-
tion was defined as the period between the initiation of 
RT and either a diagnosis of local recurrence or the date 
of the last follow-up.  Late adverse events were defined 
as adverse events emerging at least 92 days after com-
pletion of RT and were graded according to the 
Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0.
Statistical analysis. Differences in patient char-
acteristics and treatment details between the CS group 
and the without-CS groups were compared using 
Fisher’s exact test (categorical variables),  Student’s t-test 
(normally distributed continuous variables),  and 
Wilcoxon signed-rank test (non-normally distributed 
continuous variables).  LC was estimated using the 
Kaplan－Meier method.  Differences between factors 
were examined using the log-rank test.  Receiver oper-
ating characteristics (ROC) curve analysis was per-
formed to select the most relevant threshold.  The 
Kaplan－Meier curve was plotted with SPSS software 
v. 20 (IBM,  Armonk,  NY,  USA),  and other statistical 
analyses were performed using JMP software v. 10.0 
(SAS Institute,  Cary,  NC,  USA).  A two-sided p-value 
< 0.05 was considered statistically significant.
Results
Patient characteristics are summarized in Table 1 
and treatment details are provided in Table 2.  Overall,  
patients showed a median follow-up period of 29.3 
months (range 6.9-60.4 months).  Further,  4 patients 
(10.2%) developed local recurrence.  The 2-year LC rate 
was 91% (Fig. 1).  Next,  ROC analysis was used to 
determine each cutoff parameter,  and the results of the 
univariate analysis of the prognostic factors for LC are 
summarized in Table 3.  Moreover,  tumor size 
(≥ 4.3 cm) and D90 (≥ 67.7 Gy) of HR-CTV were signifi-
cant factors.
Thereafter,  the patients were divided into 2 groups:  
with CS or without CS.  The differences in patient back-
ground between the groups are also listed in Table 1 and 
Table 2.  In each group,  ROC analysis was used to 
determine each cutoff parameter for tumor size and D90 
for local control.  In the CS group,  the cutoff values of 
tumor size and D90 were 4.3 cm (AUC: 0.75) and 
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Table 1　 Patient characteristics (n=39)
Characteristics Total (n=39) With CS (n=21) Without CS (n=18) p value
Number of patients (n)
Age (years) Median (range) 59 (28-86) 59 (28-79) 59.5 (47-86) 0.39＊
FIGO 2008 IB1  7  5  2 -
IIA1  3  1  2
IIA2  3  1  2
IIB 19 12  7
IIIB  4  1  3
IVA  3  1  2
Lymph node metastasis Positive 17  6 11 0.042†
Negative 22 15  7
Histologic type SCC 39 21 18 -
Initial tumor size (mm) Median (range) 40 (20-76) 39 (20-58) 　48 (21-76) 0.02¶
Para-aortic node metastasis Positive  7  2  5 0.14†
Negative 32 19 13
SCC,  squamous cell carcinoma; FIGO,  International Federation of Gynecology and Obstetrics.
＊,  Wilcoxon signed-rank test; †,  Fisherʼs exact test; ¶,  Studentʼs t-test.
67.7 Gy (AUC: 0.84),  respectively.  In the group with-
out CS,  the cutoff values of tumor size and D90 were 
5.3 cm (AUC: 0.75) and 73.7 Gy (AUC: 0.78),  respec-
tively.  To visualize tumor size and D90 in local recurrent 
cases,  scatter diagrams of the 2 groups are shown in 
Fig. 2A and B,  where the cutoff values for these param-
eters are also shown.  Late adverse events in the rectum,  
bladder,  and sigmoid are shown in Table 4.  Further,  
grades 2 and 3 proctitis were observed in 1 (rectum 
D90: 55.1 Gy) and 2 patients (rectum D90: 62.5 and 
51.5 Gy),  respectively.  None of the patients experi-
enced higher than grade 2 cystitis or other gastrointes-
tinal morbidity.
Discussion
Traditionally,  cervical cancer has been treated using 
chemotherapy and radiotherapy,  and a variety of radio-
therapy approaches have been considered to improve 
the outcomes in these patients.  Here,  we have con-
firmed similar or better outcomes than in previous 
reports using CT-based IGBT [7-10].  We identified D90 
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Table 2　 Treatment details (n=39)
EBRT technique Total (n=39) With CS (n=21) Without CS (n=18) p value
WP (3D-CRT) 15 10  5 0.17†
WP (VMAT) 24 11 13
EBRT dose
Median total dose (Gy) (range) 56 (46-61) 50 (50-60.4) 59 (46-61) 0.004＊
Median WP dose (Gy) (range) 40 (20-50.4) 30.6 (20-40) 45 (45-50.4) <0.001＊
Median CS dose (Gy) (range) 10 (0-30) 19.8 (10-30)  0 <0.001＊
Brachytherapy
Median number of fractions (range) 3 (1-5) 4 (2-5) 3 (1-3) <0.001＊
IC 36 21 15 0.089†
IC+ IS  3  0  3
Overall treatment duration (days)
Median (range) 45 (38-63) 44 (42-52) 49.5 (38-63) 0.001＊
Chemotherapy
No  9  3  6 0.15†
Yes 30 18 12
wCDDP 26 17  9
wCDGP  4  1  3
EQD2 of the HR-CTV D90 (Gy)
Median (range) 71.9 (54-93.2) 67.8 (54-93.2) 73.1 (65.9-80.6) 0.083¶
EQD2 of the rectum D2 cc (Gy)
Median (range) 56.3 (34.8-74.4) 52.3 (34.8-73) 　63 (48.7-74.4) 0.022¶
EQD2 of the bladder D2 cc (Gy)
Median (range) 72.5 (53.1-108.2) 71.1 (53.1-108.2) 72.6 (58.2-84.6) 0.88＊
WP,  whole pelvis; CS,  central shielding; 3D-CRT,  three-dimentional conformal radiotherapy; VMAT,  volumetric modulated arc therapy; 
IC,  intracavitary; IS,  interstitial; CDDP,  cisplatin; CDGP,  nedaplatin; HR-CTV,  high-risk clinical target volume; EQD2,  equivalent dose 















Fig. 1　 Kaplan－Meier curves for local control (LC,  solid line).
and tumor size as significant factors for local control 
using univariate analysis.  Our study also suggests that 
the treatment intensity needs to be changed in the pres-
ence of CS.
Several studies have indicated an association 
between local control and tumor size.  Potter et al.  [15] 
reported a decrease in tumor control for tumors larger 
than 5 cm in treatments using MRI-based 3D-IGBT.  
CS was not used in their treatment schedule.  On the 
other hand,  in a study by Kawashima et al.  [6],  treat-
ment using CT-based 3D-IGBT,  with inclusion of CS,  
resulted in a decrease in tumor control for tumors larger 
February 2021 Local Control of IGBT for Cervical Cancer 83
Table 3　 Univariate analyses of local recurrence within the HR-CTV (n=39)
Factors Local recurrence within the  HR-CTV (n) Total (n) p-value
Presence Absence
Age <54 0 14 14 0.14
≥54 4 21 25
Tumor size <4.3 cm 0 21 21 0.031
≥4.3 cm 4 14 18
T factor I-IIA 0 13 13 0.22
IIB-IV 4 22 26
Use of chemotherapy Yes 4 26 30 0.32
No 0  9  9
Ratiotherapy technique IMRT 4 20 24 0.052
3D-CRT 0 15 15
Use of CS Yes 2 19 21 0.64
No 2 16 18
Pelvic LN metastasis Yes 1 16 17 0.43
No 3 19 22
Para-aortic LN metastasis Yes 0  7  7 0.35
No 4 28 32
HR-CTV D90 <67.7 Gy 3  7 10 0.019
≥67.7 Gy 1 28 29
Overall treatment time <48 days 1 22 23 0.14
≥48 days 3 13 16
































Cutoff value of CS group
D90 ≥ 67.7 Gy（AUC 0.84）
Tumor size ≥ 4.3 cm（AUC 0.75）
Cutoff value of without CS group
D90 ≥ 73.7 Gy（AUC 0.78）
Tumor size ≥ 5.3 cm（AUC 0.75）
A B
Fig. 2　 Scatter diagrams for local relapse in the (A) CS group and (B) without CS group.
than 4.5 cm.  The cutoff values determined for the CS 
and without-CS groups (CS -: 5.3 cm; CS +: 4.3 cm) 
in our study were similar to those in previous reports 
[6 , 15].
Our present findings also confirm that the cut-off 
values of D90 for local control differ according to 
whether or not CS is used.  Tamaki et al.  [16 , 17] 
reported a comparison of point A doses between the 
Japanese (with CS) and Western (without CS) treatment 
schedules using a phantom.  They observed that the 
dose calculation based on the Japanese treatment 
schedule suggested a cumulative dose of WP-EBRT plus 
D90 of BT,  although 13-35% of the EBRT dose with a 
4 cm width CS dose contributed to tumor control.  
Although the cutoff value for tumor control reported by 
Murakami et al.  was D90 ≥ 60 Gy,  it is possible that addi-
tional doses were prescribed as in the report by Tamaki 
and colleagues.  In our study as well,  the CS-EBRT dose 
may explain the different cutoff values between the 
with- and without-CS groups,  as the calculation does 
not include the CS-EBRT contribution.  However,  in an 
IGBT that adjusts the dose distribution based on the 
tumor size and position,  it is difficult to accurately 
understand the amount of the EBRT doses with CS that 
contributes to tumor control.  The cutoff value of D90 
calculated in our study was lower than that in the 
reports from the West [7-9],  which could be the result 
of the inclusion of nonsquamous cell carcinoma sam-
ples in those studies,  as opposed to the radio-sensitive 
squamous cell carcinoma cohort analyzed in our study.  
Further,  reports by Kawashima et al.  [6] and other 
groups [18 , 19] suggest that adenocarcinoma is a signif-
icant risk factor for local control.  Additionally,  the 
present study is based on CT-based IGBT and,  as 
reported by Viswanathan et al.  [20],  CT overestimates 
the volume of HR-CTV over MRI,  which results in 
lower D90 values.
However,  it should be noted that the present study 
was a retrospective study with a small sample size.  
Moreover,  tumor size was significantly higher in the 
without-CS group than in the CS group.  Although our 
results showed that D90 ≥ 73.7 Gy provided more reliable 
local control in the without-CS group,  this dose may be 
too high for small lesions and could lead to more 
adverse events in OARs.  In the future,  it will be neces-
sary to formulate a treatment schedule without CS and 
set a target dose according to tumor size.
In conclusion,  this study confirms the favorable 
outcome observed with CT-based IGBT.  Tumor size 
and D90 were significant factors for local control.  It 
should be understood that the use of CS complicates the 
current understanding regarding the treatment intensity 
required for local control.  Finally,  our study provides 
important findings regarding the dose required for local 
control both with and without CS.
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